Effects of L-dopa or amantadine treatment on the spindles of sleep in Parkinson's syndromes
Puca, F.M.; Bricolo, A.; Turella, G.
Revue Neurologique (Paris) 127(2): 313
1972
ISSN/ISBN: 0035-3787 PMID: 4666639 Document Number: 52569
Document emailed within 1 workday
Related Documents
Pendefunda, G.; Pollingher, B.; Stefanache, F.; Gavril, A.; Oprisan, C.; Merling, M.; Nemteanu, E.; Ciunru, M.; Koropitzer, I. 1975: The treatment with L-dopa and amantadine in Parkinson's disease Therapia Hungarica 23(1): 12-16Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Dzudza, M.; Dzudza, D. 1974: Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease Medicinski Arhiv 28(4): 407-415
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Ambrosetto, C.; Martinelli, P. 1971: Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa Minerva Medica 62(82): 4017-4019
Ciuca, I.; Bulandra, R.; Serbanesco, L.; Ninosu, N. 1972: Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes Revue Neurologique (Paris) 127(2): 305-308
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Ferraris, M. 1971: Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa Minerva Medica 62(82): 3971-3973
Rabadeau Dumas, J.L.; Rondot, P.; Cardon, P. 1977: Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor Therapie 32(2): 161-172
Juvancz, P. 1981: The sleep of artificially reared newborn rats, effect of alpha-methyl-DOPA treatment on paradoxical sleep and on adult behaviour Acta Physiologica Academiae Scientiarum Hungaricae 57(1): 87-98
Campanella, G.; Zallone, E.; Buscaino, G.A. 1972: Amantadine in the treatment of Parkinson's syndrome: studied in 31 patients for 3 months Acta Neurologica 27(5): 491-500
Fasano, V.A.; Urciuoli, R.; Broggi, G. 1971: On the treatment of Parkinson's disease with intravenous administration of amantadine (77 cases) Minerva Medica 62(82): 3968-3970
Lombardo, L. 1973: Efficacy and side effects of L-dopa in patients with Parkinson's syndrome Archivos de Investigacion Medica 4(3): 215-224
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Andrews, C.J. 1972: Amantadine and L-dopa Australian and New Zealand Journal of Medicine 2(3): 292-293
Völler, G. 1970: L-dopa in the treatment of Parkinson's disease Die Medizinische Welt 27: 1267-1268
Glabb, J.; Hübner, W.; Glabb, S. 1973: Treatment of Parkinson's syndrome using L-dopa. 2 Zeitschrift für Arztliche Fortbildung 67(15): 745-753
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547